ReCode Therapeutics

ReCode Therapeutics' Mission

ReCode Therapeutics is dedicated to developing groundbreaking therapeutics for genetically defined diseases that currently lack treatment options. Their focus includes debilitating conditions such as primary ciliary dyskinesia and cystic fibrosis. By targeting these rare and often overlooked diseases, ReCode aims to fill critical gaps in the medical landscape and improve the quality of life for patients with these genetic disorders.

ReCode Therapeutics' SORT LNP Platform

ReCode Therapeutics utilizes the SORT LNP platform, a first-in-class modular technology designed for the targeted delivery of genetic medicines. This innovative platform enables the precise delivery of therapeutic agents to various organs, tissues, and cells, extending beyond the liver. The SORT LNP platform enhances the efficacy and safety of genetic treatments by ensuring that they reach the intended target areas, thus maximizing therapeutic outcomes and minimizing off-target effects.

ReCode Therapeutics' Pipeline

ReCode Therapeutics boasts a robust pipeline of rare disease therapeutics that leverage optimized mRNA and gene correction technologies. One of the distinctive features of their pipeline is the capability for redosing, which is crucial for managing chronic conditions and ensuring sustained therapeutic benefits. This pipeline underscores ReCode’s commitment to advancing innovative genetic treatments and providing long-term solutions for patients with rare genetic disorders.

ReCode Therapeutics and Cystic Fibrosis Foundation Collaboration

ReCode Therapeutics collaborates with the Cystic Fibrosis Foundation to propel preclinical research and early-stage clinical trials aimed at developing novel therapies for cystic fibrosis. This partnership is pivotal in accelerating the translation of scientific discoveries into potential treatments. By combining ReCode's technological expertise with the Foundation's resources and support, this collaboration seeks to make significant strides in the fight against cystic fibrosis, offering hope to patients and families affected by this challenging condition.

ReCode Therapeutics' Headquarters

ReCode Therapeutics is headquartered at 1140 O’Brien Drive, Menlo Park, CA 94025. Located in the heart of the biotech innovation hub, the company's headquarters provides a strategic advantage for fostering innovation and collaboration. This prime location enables ReCode to attract top talent and engage with leading biotech firms, research institutions, and investors, facilitating the advancement of their pioneering therapies.